OneSource Specialty Pharma shares fall after Q4 profit drops sharply despite stable revenue
Sarthak Kumar
Shares of OneSource Specialty Pharma declined over 3% on Wednesday after the company reported a sharp fall in quarterly profitability despite largely stable revenue performance.
The stock was trading around ₹1,773 on the NSE, down over 3% from the previous close.
For the quarter ended March 2026, the company reported a net profit of ₹4.6 crore, sharply lower compared to ₹98.5 crore reported in the same quarter last year.
Revenue from operations, however, remained broadly stable and rose 1% year-on-year to ₹428.2 crore from ₹426 crore.
Operational performance weakened significantly during the quarter. EBITDA fell 50% YoY to ₹92 crore compared to ₹182 crore in Q4FY25. EBITDA margin also contracted sharply to 21.5% from 42.7% a year ago.
The company also reported a loss before tax of ₹3 crore during the quarter compared to a profit before tax of ₹84 crore in the corresponding quarter last year.
The filing further showed pressure in the company’s CDMO (Contract Development and Manufacturing Organisation) segment profitability.
According to the segment data disclosed by the company, CDMO segment revenue stood at ₹428.2 crore during Q4FY26 compared to ₹425.9 crore in Q4FY25. However, segment profit before tax for the CDMO business declined sharply to a loss of ₹0.3 crore versus a profit of ₹83.5 crore in the year-ago quarter.
On a sequential basis as well, CDMO segment performance remained under pressure. The segment had reported a loss before tax of ₹93 crore in the December 2025 quarter.
For the full financial year FY26, CDMO segment revenue stood at ₹1,421.6 crore compared to ₹1,444.9 crore in FY25. The segment reported a pre-tax loss of ₹92 crore for FY26 against a loss of ₹67.8 crore in the previous financial year.
The company’s segment assets for the CDMO business stood at ₹6,756.8 crore as of March 31, 2026, compared to ₹6,383 crore a year earlier.
Investors appeared concerned about the sharp decline in margins and profitability despite stable topline growth, leading to weakness in the stock during Wednesday’s trade.